Stockscreener 앱 받기
12.44
8.19%
-1.11
시간 외 거래:
12.69
0.25
+2.01%
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock - Investing.com India
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com - Investing.com South Africa
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares By Investing.com - Investing.com India
Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock - Investing.com UK
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares - Investing.com UK
Lyell Immunopharma (LYEL) CEO’s 388-share tax-related stock sale detailed in Form 4 - Stock Titan
Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares - Stock Titan
Lyell Immunopharma (LYEL) COO’s 89-share sale tied to RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting - TipRanks
Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections - Stock Titan
Citizens upgrades Lyell Immunopharma stock price target on trial progress By Investing.com - Investing.com Canada
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL) - Seeking Alpha
Lyell Immunopharma issues colorectal cancer drug safety update - MSN
Director at Lyell Immunopharma (LYEL) receives new option grant - Stock Titan
[Form 4] Lyell Immunopharma, Inc. Insider Trading Activity - Stock Titan
Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director granted 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250-share option grant - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250 options at $13.22 strike - Stock Titan
Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22 - Stock Titan
Lyell reports safety data for ronde-cel in lymphoma trial By Investing.com - Investing.com Canada
Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma - TradingView
New Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell Immunopharma - Quiver Quantitative
Over 100 lymphoma patients get CAR-T with no Grade 3+ CRS - Stock Titan
Lyell Immunopharma (LYEL) CMO logs small tax-driven stock sale on Form 4 - Stock Titan
LYEL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
H.C. Wainwright reiterates Lyell Immunopharma stock rating on safety data By Investing.com - Investing.com Canada
Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Citizens upgrades Lyell Immunopharma stock rating on safety data By Investing.com - Investing.com Canada
Lyell Immunopharma amends LYL273 Phase 1 trial to Phase 1/2 - grafa.com
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update - Benzinga
Lyell Immunopharma stock rises on trial amendment - Investing.com UK
Lyell Immunopharma stock rises on trial amendment By Investing.com - Investing.com Canada
Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study - Moomoo
Lyell Immunopharma Reports Significant Reduction in Grade ≥ 2 Diarrhea/Colitis in Phase 1 Trial of LYL273 for Metastatic Colorectal Cancer with GI Prophylaxis - Quiver Quantitative
Lyell Immunopharma Provides Update on Safety Profile of - GlobeNewswire
New regimen cuts gut side effects in Lyell's LYL273 colon cancer trial - Stock Titan
Lyell Immunopharma, Inc.Common Stock (NQ: LYEL - FinancialContent
Lyell to present ronde-cel lymphoma trial data at EHA congress - Investing.com Australia
Lyell Immunopharma to Present Phase 1/2 Ronde-Cel Safety and Translational Data in Large B-Cell Lymphoma at EHA 2026Profit Recovery Report - newsline.com
Lyell to present ronde-cel lymphoma trial data at EHA congress By Investing.com - Investing.com South Africa
Lyell Immunopharma to Present Phase 1/2 Clinical Trial Data on Rondecabtagene Autoleucel at EHA 2026 Congress - Quiver Quantitative
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress - GlobeNewswire
Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Lyell Immunopharma, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 150% Upside - TradingView
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
Lyell Immunopharma Q1 2026 Earnings: EPS Beats Estimates by 54.4% as Stock Declines 13.18% - newsline.com
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times
Lyell Quiet as Bigger CAR-T Question Lingers for Investors - Bez Kabli
Lyell Immunopharma (LYEL) Holds Steady With Modest Gains Amid Technical ConsolidationFactor ETF Flow - newsline.com
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances - Yahoo Finance
Lyell Immunopharma (LYEL) Falls Sharply: Key Support Levels in Focus After 6.9% DropFund Manager Survey - The Legal Advocate
Lyell Immunopharma Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesOperating Margin Analysis - newsline.com
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL) - MSN
Lyell Immunopharma stock (US55083R1041): Analyst boosts price target as cell therapy pipeline advanc - AD HOC NEWS
1.27%
1.43%
자본화:
|
볼륨(24시간):